U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

WHO Guidelines for malaria [Internet]. Geneva: World Health Organization; 2022 Feb 18.

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of WHO Guidelines for malaria

WHO Guidelines for malaria [Internet].

Show details

References

1.
WHO Handbook for Guideline Development 2nd edition. Geneva: World Health Organization 2014; Website
2.
International travel and health. Geneva: World Health Organization 2012; Website
3.
World malaria report 2020. Geneva: World Health Organization 2020; Website
4.
Global technical strategy for malaria 2016-2030. Geneva: World Health Organization 2015; Website
5.
High burden to high impact: a targeted malaria response. Geneva: World Health Organization 2018; Website
6.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. : GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed.) 2008;336(7650):924–6 Pubmed Journal [PMC free article: PMC2335261] [PubMed: 18436948]
7.
A framework for malaria elimination. Geneva: World Health Organization 2017; Website
8.
Yekutiel P : Problems of epidemiology in malaria eradication. Bulletin of the World Health Organization 1960;22 669–83 Pubmed [PMC free article: PMC2555342] [PubMed: 13846510]
9.
Cameron E, Battle KE, Bhatt S, Weiss DJ, Bisanzio D, Mappin B, et al. : Defining the relationship between infection prevalence and clinical incidence of Plasmodium falciparum malaria. Nature communications 2015;6 8170 Pubmed Journal [PMC free article: PMC4569718] [PubMed: 26348689]
10.
Cox J, Sovannaroth S, Dy Soley L, Ngor P, Mellor S, Roca-Feltrer A : Novel approaches to risk stratification to support malaria elimination: an example from Cambodia. Malaria journal 2014;13 371 Pubmed Journal [PMC free article: PMC4177243] [PubMed: 25233886]
11.
A research agenda for malaria eradication: monitoring, evaluation, and surveillance. PLoS medicine 2011;8(1):e1000400 Pubmed Journal [PMC free article: PMC3026689] [PubMed: 21311581]
12.
Investing to overcome the global impact of neglected tropical diseases. Geneva: World Health Organization 2015; Website
13.
Global vector control response 2017–2030. World Health Organization, Geneva 2017; Website
14.
Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. : The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature 2015;526(7572):207–211 Pubmed Journal [PMC free article: PMC4820050] [PubMed: 26375008]
15.
Framework for a national vector control needs assessment. Geneva: World Health Organization 2017; Website
16.
WHO malaria threats map. Geneva: World Health Organization 2021; Website
17.
Kafy HT, Ismail BA, Mnzava AP, Lines J, Abdin MSE, Eltaher JS, et al. : Impact of insecticide resistance in Anopheles arabiensis on malaria incidence and prevalence in Sudan and the costs of mitigation. Proceedings of the National Academy of Sciences of the United States of America 2017;114(52):E11267–E11275 Pubmed Journal [PMC free article: PMC5748194] [PubMed: 29229808]
18.
Kleinschmidt I, Bradley J, Knox TB, Mnzava AP, Kafy HT, Mbogo C, et al. : Implications of insecticide resistance for malaria vector control with long-lasting insecticidal nets: a WHO-coordinated, prospective, international, observational cohort study. The Lancet. Infectious diseases 2018;18(6):640–649 Pubmed Journal [PMC free article: PMC5968369] [PubMed: 29650424]
19.
Global plan for insecticide resistance management in malaria vectors. Geneva: World Health Organization 2012; Website
20.
Test procedures for insecticide resistance monitoring in malaria vector mosquitoes, 2nd ed. Geneva: World Health Organization 2016; Website
21.
Framework for a national plan for monitoring and management of insecticide resistance in malaria vectors. Geneva: World Health Organization 2017; Website
22.
Lissenden N., Churcher T., Hancock P., Ismail HM, Kont M., Lambert B., et al. : Reviewing the evidence for and against selection of specific pyrethroids for programmatic purposes. Liverpool Insect Testing Establishment 2021; Website [PMC free article: PMC8465213] [PubMed: 34564266]
23.
Insecticide-treated nets for malaria transmission control in areas with insecticide-resistant mosquito populations: preferred product characteristics. Geneva: World Health Organization 2021; Website
24.
Prequalified lists: vector control products (website). Geneva: World Health Organization 2021; Website
25.
REX Consortium : Heterogeneity of selection and the evolution of resistance. Trends in ecology & evolution 2013;28(2):110–8 Pubmed Journal [PubMed: 23040463]
26.
Sternberg ED, Thomas MB : Insights from agriculture for the management of insecticide resistance in disease vectors. Evolutionary applications 2018;11(4):404–414 Pubmed Journal [PMC free article: PMC5891047] [PubMed: 29636795]
27.
Huijben S, Paaijmans KP : Putting evolution in elimination: Winning our ongoing battle with evolving malaria mosquitoes and parasites. Evolutionary applications 2018;11(4):415–430 Pubmed Journal [PMC free article: PMC5891050] [PubMed: 29636796]
28.
South A, Hastings IM : Insecticide resistance evolution with mixtures and sequences: a model-based explanation. Malaria journal 2018;17(1):80 Pubmed Journal [PMC free article: PMC5815191] [PubMed: 29448925]
29.
Malaria surveillance, monitoring and evaluation: a reference manual. Geneva: World Health Organization 2018; Website
30.
Risks associated with scale-back of vector control after malaria transmission has been reduced. Information note. Geneva: World Health Organization 2015; Website
31.
Norms, standards and processes underpinning development of WHO recommendations on vector control. Geneva: World Health Organization 2020; Website
32.
Stockholm Convention on Persistent Organic Pollutants (POPS). United Nations Environment Programme 2018; Website
33.
ter Kuile FO, Terlouw DJ, Phillips-Howard PA, Hawley WA, Friedman JF, Kolczak MS, et al. : Impact of permethrin-treated bed nets on malaria and all-cause morbidity in young children in an area of intense perennial malaria transmission in western Kenya: cross-sectional survey. The American journal of tropical medicine and hygiene 2003;68(4 Suppl):100–7 Pubmed [PubMed: 12749492]
34.
Gimnig JE, Kolczak MS, Hightower AW, Vulule JM, Schoute E, Kamau L, et al. : Effect of permethrin-treated bed nets on the spatial distribution of malaria vectors in western Kenya. The American journal of tropical medicine and hygiene 2003;68(4 Suppl):115–20 Pubmed [PubMed: 12749494]
35.
Gimnig JE, Vulule JM, Lo TQ, Kamau L, Kolczak MS, Phillips-Howard PA, et al. : Impact of permethrin-treated bed nets on entomologic indices in an area of intense year-round malaria transmission. The American journal of tropical medicine and hygiene 2003;68(4 Suppl):16–22 Pubmed [PubMed: 12749481]
36.
Phillips-Howard PA, Nahlen BL, Kolczak MS, Hightower AW, ter Kuile FO, Alaii JA, et al. : Efficacy of permethrin-treated bed nets in the prevention of mortality in young children in an area of high perennial malaria transmission in western Kenya. The American journal of tropical medicine and hygiene 2003;68(4 Suppl):23–9 Pubmed [PubMed: 12749482]
37.
Hawley WA, Phillips-Howard PA, ter Kuile FO, Terlouw DJ, Vulule JM, Ombok M, et al. : Community-wide effects of permethrin-treated bed nets on child mortality and malaria morbidity in western Kenya. The American journal of tropical medicine and hygiene 2003;68(4 Suppl):121–7 Pubmed [PubMed: 12749495]
38.
D’Alessandro U, Olaleye BO, McGuire W, Langerock P, Bennett S, Aikins MK, et al. : Mortality and morbidity from malaria in Gambian children after introduction of an impregnated bednet programme. Lancet (London, England) 1995;345(8948):479–83 Pubmed [PubMed: 7861874]
39.
Quiñones ML, Lines J, Thomson MC, Jawara M, Greenwood BM : Permethrin-treated bed nets do not have a ‘mass-killing effect’ on village populations of Anopheles gambiae s.l. in The Gambia. Transactions of the Royal Society of Tropical Medicine and Hygiene 92(4):373–8 Pubmed [PubMed: 9850383]
40.
Snow RW, Lindsay SW, Hayes RJ, Greenwood BM : Permethrin-treated bed nets (mosquito nets) prevent malaria in Gambian children. Transactions of The Royal Society of Tropical Medicine and Hygiene 1988; Journal Website [PubMed: 2908286]
41.
Russell TL, Lwetoijera DW, Maliti D, Chipwaza B, Kihonda J, Charlwood JD, et al. : Impact of promoting longer-lasting insecticide treatment of bed nets upon malaria transmission in a rural Tanzanian setting with pre-existing high coverage of untreated nets. Malaria journal 2010;9 187 Pubmed Journal [PMC free article: PMC2902500] [PubMed: 20579399]
42.
Govella NJ, Okumu FO, Killeen GF : Insecticide-treated nets can reduce malaria transmission by mosquitoes which feed outdoors. The American journal of tropical medicine and hygiene 2010;82(3):415–9 Pubmed Journal [PMC free article: PMC2829902] [PubMed: 20207866]
43.
Birget PLG, Koella JC : An Epidemiological Model of the Effects of Insecticide-Treated Bed Nets on Malaria Transmission. PloS one 2015;10(12):e0144173 Pubmed Journal [PMC free article: PMC4670222] [PubMed: 26636568]
44.
Pryce J, Richardson M, Lengeler C : Insecticide-treated nets for preventing malaria. Cochrane Database of Systematic Reviews 2018;(11): Pubmed Journal Website [PMC free article: PMC6418392] [PubMed: 30398672]
45.
Gleave K, Lissenden N, Richardson M, Choi L, Ranson H : Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa. The Cochrane database of systematic reviews 2018;11 CD012776 Pubmed Journal [PMC free article: PMC6262905] [PubMed: 30488945]
46.
Protopopoff N, Mosha JF, Lukole E, Charlwood JD, Wright A, Mwalimu CD, et al. : Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two factorial design trial. Lancet (London, England) 2018;391(10130):1577–1588 Pubmed Journal [PMC free article: PMC5910376] [PubMed: 29655496]
47.
Churcher TS, Lissenden N, Griffin JT, Worrall E, Ranson H : The impact of pyrethroid resistance on the efficacy and effectiveness of bednets for malaria control in Africa. eLife 2016;5 Pubmed Journal [PMC free article: PMC5025277] [PubMed: 27547988]
48.
Achieving and maintaining universal coverage with long-lasting insecticidal nets for malaria control. Geneva: World Health Organization 2017; Website
49.
WHO recommendations on the sound management of old long-lasting insecticidal nets. Geneva: World Health Organization 2014; Website
50.
Pluess B, Tanser FC, Lengeler C, Sharp BL : Indoor residual spraying for preventing malaria. The Cochrane database of systematic reviews 2010;(4):CD006657 Pubmed Journal [PMC free article: PMC6532743] [PubMed: 20393950]
51.
Meeting report on the WHO Evidence Review Group on assessing comparative effectiveness of new vector control tools. Geneva: World Health Organization 2017; Website
52.
Indoor residual spraying: An operational manual for IRS for malaria transmission, control and elimination. 2nd edition. Geneva: World Health Organization 2015; Website
53.
Choi L, Pryce J, Garner P : Indoor residual spraying for preventing malaria in communities using insecticide-treated nets. Cochrane Database of Systematic Reviews 2019;(5): Pubmed Journal Website [PMC free article: PMC6532761] [PubMed: 31120132]
54.
WHO Guidance for countries on combining indoor residual spraying and long-lasting insecticidal nets. Geneva: World Health Organization 2014 ; Website
55.
Sluydts V, Durnez L, Heng S, Gryseels C, Canier L, Kim S, et al. : Efficacy of topical mosquito repellent (picaridin) plus long-lasting insecticidal nets versus long-lasting insecticidal nets alone for control of malaria: a cluster randomised controlled trial. The Lancet. Infectious diseases 2016;16(10):1169–1177 Pubmed Journal [PubMed: 27371977]
56.
WHO Housing and health guidelines. Geneva: World Health Organization 2018; Website [PubMed: 30566314]
57.
Keeping the vector out: housing improvements for vector control and sustainable development. Geneva: World Health Organization 2017; Website
58.
Tusting LS, Bottomley C, Gibson H, Kleinschmidt I, Tatem AJ, Lindsay SW, et al. : Housing Improvements and Malaria Risk in Sub-Saharan Africa: A Multi-Country Analysis of Survey Data. PLoS medicine 2017;14(2):e1002234 Pubmed Journal [PMC free article: PMC5319641] [PubMed: 28222094]
59.
Choi L, Majambere S, Wilson AL : Larviciding to prevent malaria transmission. Cochrane Database of Systematic Reviews 2019;(8): Pubmed Journal Website [PMC free article: PMC6699674] [PubMed: 31425624]
60.
Larval source management: a supplementary measure for malaria vector control. An operational manual. Geneva: World Health Organization 2013; Website
61.
Walshe DP, Garner P, Adeel AA, Pyke GH, Burkot TR : Larvivorous fish for preventing malaria transmission. Cochrane Database of Systematic Reviews 2017;(12): Pubmed Journal Website [PMC free article: PMC5741835] [PubMed: 29226959]
62.
Maia MF, Kliner M, Richardson M, Lengeler C, Moore SJ : Mosquito repellents for malaria prevention. Cochrane Database of Systematic Reviews 2018;(2): Pubmed Journal Website [PMC free article: PMC5815492] [PubMed: 29405263]
63.
Pryce J, Choi L, Richardson M, Malone D : Insecticide space spraying for preventing malaria transmission. Cochrane Database of Systematic Reviews 2018;(11): Pubmed Journal Website [PMC free article: PMC6516806] [PubMed: 30388303]
64.
Furnival-Adams JA, Olanga EA, Napier M, Garner M : House modifications for preventing malaria. Cochrane Database of Systematic Reviews 2021;(1): Pubmed Journal Website [PMC free article: PMC8642787] [PubMed: 33471371]
65.
Guidance note on the control of residual malaria parasite transmission. Geneva: World Health Organization 2014; Website
66.
Malaria control in humanitarian emergencies: an inter-agency field handbook, 2nd ed. Geneva: World Health Organization 2013; Website
67.
Global strategic framework for integrated vector management. Geneva: World Health Organization 2004; Website
68.
Indoor residual spraying: use of indoor residual spraying for scaling up global malaria control and elimination. Geneva: World Health Organization 2006; Website
69.
Seventieth World Health Assembly : Agenda item 14.2. Global vector control response: an integrated approach for the control of vector-borne diseases. WHA70.16 31 May 2017;
70.
Ethical issues associated with vector-borne diseases. Report of a scoping meeting, 23–24 February 2017. Geneva: World Health Organization 2017; Website
71.
Roadmap for action 2014–2019: integrating equity, gender, human rights and social determinants into the work of WHO. Geneva: World Health Organization 2015; Website
72.
White MT, Conteh L, Cibulskis R, Ghani AC : Costs and cost-effectiveness of malaria control interventions--a systematic review. Malaria journal 2011;10 337 Pubmed Journal [PMC free article: PMC3229472] [PubMed: 22050911]
73.
Core structure for training curricula on integrated vector management. Geneva: World Health Organization 2012; Website
74.
A model quality assurance system for procurement agencies: recommendations for quality assurance systems focusing on prequalification of products and manufacturers, purchasing, storage and distribution of pharmaceutical products. Geneva: World Health Organization 2007; Website
75.
How to design vector control efficacy trials: guidance on phase III vector control field trial design (provided by the Vector Control Advisory Group). Geneva: World Health Organization 2017; Website
76.
White NJ : How antimalarial drug resistance affects post-treatment prophylaxis. Malaria journal 2008;7 9 Pubmed Journal [PMC free article: PMC2254426] [PubMed: 18186948]
77.
Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J : Mass drug administration for malaria. The Cochrane database of systematic reviews 2013;(12):CD008846 Pubmed Journal [PMC free article: PMC4468927] [PubMed: 24318836]
78.
The role of mass drug administration, mass screening and treatment, and focal screening and treatment for malaria. Geneva: World Health Organization 2015; Website
79.
Guidance on temporary malaria control measures in Ebola-affected countries. Geneva: World Health Organization 2014; Website
80.
Mass drug adminiatration for falciparum malaria: a pratical field manual. Geneva: World Health Organization 2017; Website
81.
Kayentao K, Garner P, van Eijk AM, Naidoo I, Roper C, Mulokozi A, et al. : Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. JAMA 2013;309(6):594–604 Pubmed Journal [PMC free article: PMC4669677] [PubMed: 23403684]
82.
WHO policy brief for the implementation of intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP)SP. Geneva: World Health Organization 2014; Website
83.
Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, et al. : Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet (London, England) 2009;374(9700):1533–42 Pubmed Journal [PubMed: 19765816]
84.
Policy recommendation on intermittent preventive treatment during infancy with sulphadoxine-pyrimethamine (SP-IPTi) for Plasmodium falciparum malaria control in Africa. Geneva: World Health Organization 2010; Website
85.
Meremikwu MM, Donegan S, Sinclair D, Esu E, Oringanje C : Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. The Cochrane database of systematic reviews 2012;(2):CD003756 Pubmed Journal [PMC free article: PMC6532713] [PubMed: 22336792]
86.
Seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine in children: A field guide. Geneva: World Health Organization 2013; Website
87.
Immunization Agenda 2030: A Global Strategy to Leave No One Behind. World Health Organization 1 April 2020; Website
88.
Full evidence report on the RTS,S/AS01 malaria vaccine. Geneva: World Health Organization 2021; Website
89.
Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet (London, England) 2015;386(9988):31–45 Pubmed Journal [PMC free article: PMC5626001] [PubMed: 25913272]
90.
Mosquirix: Opinion on medicine for use outside EU. European Medicines Agency Website
91.
Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga R-S, Diarra M, et al. : Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention. The New England journal of medicine 2021;385(11):1005–1017 Pubmed Journal [PubMed: 34432975]
92.
Datoo MS, Natama MH, Somé A, Traoré O, Rouamba T, Bellamy D, et al. : Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet (London, England) 2021;397(10287):1809–1818 Pubmed Journal [PMC free article: PMC8121760] [PubMed: 33964223]
93.
Butler D : Promising malaria vaccine to be tested in first large field trial. Nature 2019; Journal Website [PubMed: 32291409]
94.
Minassian AM : Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. 2021; Website [PMC free article: PMC8240500] [PubMed: 34223402]
95.
Draper SJ, Angov E, Horii T, Miller LH, Srinivasan P, Theisen M, et al. : Recent advances in recombinant protein-based malaria vaccines. Vaccine 2015;33(52):7433–43 Pubmed Journal [PMC free article: PMC4687528] [PubMed: 26458807]
96.
Adjuvant development for vaccines and for autoimmune and allergic diseases. Washington DC, United States of America. The Small Business Innovation Research and Small Business Technology Transfer. SBIR and STTR 2020; Website
97.
Guidelines on the quality, safety and efficacy of recombinant malaria vaccines targeting the pre-erythrocytic and blood stages of Plasmodium falciparum, Annex 3, TRS No 980. World Health Organization 2014; Website
98.
WHO preferred product characteristics (PPC) for malaria vaccines. Geneva: World Health Organization 2014; Website
99.
Position Paper - Malaria Vaccine. Geneva: World Health Organization 2022; Website
100.
Tinto H, Otieno W, Gesase S, Sorgho H, Otieno L, Liheluka E, et al. : Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. The Lancet. Infectious diseases 2019;19(8):821–832 Pubmed Journal [PubMed: 31300331]
101.
Milligan P, Moore K : Statistical report on the results of the RTS,S/AS01 Malaria Vaccine Pilot Evalation 24 months after the vaccine was introduced. 2021;V1.3 6 Sept 2021
102.
Penny MA, Galactionova K, Tarantino M, Tanner M, Smith TA : The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models. BMC medicine 2015;13 170 Pubmed Journal [PMC free article: PMC4518512] [PubMed: 26219380]
103.
Vekemans J, Guerra Y, Lievens M, Benns S, Lapierre D, Leach A, et al. : Pooled analysis of safety data from pediatric Phase II RTS,S/ AS malaria candidate vaccine trials. Human vaccines 2011;7(12):1309–16 Pubmed Journal [PubMed: 22108035]
104.
Proposed framework for policy decision on RTS,S/AS01 malaria vaccine for the Strategic Advisory Group of Experts (SAGE) on Immunization and the Malaria Policy Advisory Committee (MPAC). Geneva: World Health Organization 2019; Website
105.
Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, et al. : Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. The Lancet. Infectious diseases 2011;11(10):741–9 Pubmed Journal [PubMed: 21782519]
106.
Agnandji ST, Asante KP, Lyimo J, Vekemans J, Soulanoudjingar SS, Owusu R, et al. : Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. The Journal of infectious diseases 2010;202(7):1076–87 Pubmed Journal [PubMed: 20735271]
107.
Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa. 2021; [PMC free article: PMC8142305] [PubMed: 34027998]
108.
Talaat KR, Ellis RD, Hurd J, Hentrich A, Gabriel E, Hynes NA, et al. : Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults. PloS one 2016;11(10):e0163144 Pubmed Journal [PMC free article: PMC5066979] [PubMed: 27749907]
109.
Guimarães LE, Baker B, Perricone C, Shoenfeld Y : Vaccines, adjuvants and autoimmunity. Pharmacological research 2015;100 190–209 Pubmed Journal [PMC free article: PMC7129276] [PubMed: 26275795]
110.
Malaria case management: operations manual. Geneva: World Health Organization 2009; Website
111.
Integrated management of childhood illness for high HIV settings: chart booklet. Geneva: World Health Organization 2008; Website [PubMed: 23805440]
112.
Universal access to malaria diagnostic testing - an operational manual. Geneva: World Health Organization 2011; Website
113.
Malaria diagnosis: memorandum from a WHO meeting. Bulletin of the World Health Organization 1988;66(5):575–94 Pubmed [PMC free article: PMC2491192] [PubMed: 3061674]
114.
Malaria microscopy quality assurance manual, version 2. Geneva: World Health Organization 2016; Website
115.
Kawamoto F, Billingsley PF : Rapid diagnosis of malaria by fluorescence microscopy. Parasitology today (Personal ed.) 1992;8(2):69–71 Pubmed [PubMed: 15463575]
116.
Malaria diagnosis: new perspectives. Geneva: World Health Organization 2003; Website
117.
Malaria rapid diagnosis: making it work. Meeting report. World Health Organization. Regional Office for the Western Pacific 2003; Website
118.
The use of rapid diagnostic tests. World Health Organization. Regional Office for the Western Pacific 2004; Website
119.
Transporting, storing and handling malaria rapid diagnostic tests in health clinics. Geneva: World Health Organization 2009; Website
120.
Malaria rapid diagnostic test performance. Results of WHO product testing of malaria RDTs: round 5. Geneva: World Health Organization 2014; Website
121.
False-negative RDT results and implications of new reports of P. falciparum hrp 2/3 gene deletions. Geneva: World Health Organization 2017; Website
122.
Abba K, Deeks JJ, Olliaro P, Naing C-M, Jackson SM, Takwoingi Y, et al. : Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic countries. The Cochrane database of systematic reviews 2011;(7):CD008122 Pubmed Journal [PMC free article: PMC6532563] [PubMed: 21735422]
123.
Recommended selection criteria for procurement of malaria rapid diagnostic tests. Geneva: World Health Organization 2018; Website
124.
Thiam S, Thior M, Faye B, Ndiop M, Diouf ML, Diouf MB, et al. : Major reduction in anti-malarial drug consumption in Senegal after nation-wide introduction of malaria rapid diagnostic tests. PloS one 2011;6(4):e18419 Pubmed Journal [PMC free article: PMC3071817] [PubMed: 21494674]
125.
Voller A : The immunodiagnosis of malaria. In: Wernsdorfer WH, McGregor I, editors. Malaria. Principles and Practice of Malariology. Edinburgh: Churchill Livingstone 1988;1 815–827 Website
126.
Bates I, Iboro J, Barnish G : Challenges in monitoring the impact of interventions against malaria using diagnostics. In: Reducing malaria’s burden. Evidence of effectiveness for decision-makers. Global Health Council, Washington D.C. 2003; 33–39 Website
127.
WHO Evidence review group on malaria diagnosis in low transmission settings. Meeting Report. Geneva: World Health Organization 2012; Website
128.
The use of artesunate-pyronaridine for the treatment of uncomplicated malaria. Geneva: World Health Organization 2019; Website
129.
Sinclair D, Zani B, Donegan S, Olliaro P, Garner P : Artemisinin-based combination therapy for treating uncomplicated malaria. The Cochrane database of systematic reviews 2009;(3):CD007483 Pubmed Journal [PMC free article: PMC6532584] [PubMed: 19588433]
130.
Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D : Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. The Cochrane database of systematic reviews 2014;(1):CD010927 Pubmed Journal [PMC free article: PMC4470355] [PubMed: 24443033]
131.
Pyramax product information. Annex 1. Summary of product characteristics. European Medicines Agency (EMA), Europa EU Website
132.
16th meeting of the WHO Advisory Committee on Safety of Medicinal Products (ACSoMP). Geneva: World Health Organization 2019; Website
133.
Good procurement practices for artemisinin-based antimalarial medicines. Geneva: World Health Organization 2010; Website
134.
Tarning J, Zongo I, Somé FA, Rouamba N, Parikh S, Rosenthal PJ, et al. : Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clinical pharmacology and therapeutics 2012;91(3):497–505 Pubmed Journal [PMC free article: PMC3736305] [PubMed: 22258469]
135.
The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS medicine 2013;10(12):e1001564; discussion e1001564 Pubmed Journal [PMC free article: PMC3848996] [PubMed: 24311989]
136.
Graves PM, Gelband H, Garner P : Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission. The Cochrane database of systematic reviews 2014;(6):CD008152 Pubmed Journal [PMC free article: PMC4456193] [PubMed: 24979199]
137.
White NJ, Qiao LG, Qi G, Luzzatto L : Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malaria journal 2012;11 418 Pubmed Journal [PMC free article: PMC3546849] [PubMed: 23237606]
138.
Recht J, Ashley E, White N : Safety of 8-aminoquinoline antimalarial medicines. World Health Organization, Geneva 2014; Website
139.
Policy brief on single-dose primaquine as a gametocytocide in Plasmodium falciparum malaria. Geneva: World Health Organization 2015; Website
140.
McGready R, Lee SJ, Wiladphaingern J, Ashley EA, Rijken MJ, Boel M, et al. : Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. The Lancet. Infectious diseases 2012;12(5):388–96 Pubmed Journal [PMC free article: PMC3346948] [PubMed: 22169409]
141.
Mosha D, Mazuguni F, Mrema S, Sevene E, Abdulla S, Genton B : Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort. Malaria journal 2014;13 197 Pubmed Journal [PMC free article: PMC4040412] [PubMed: 24884890]
142.
Gething PW, Elyazar IRF, Moyes CL, Smith DL, Battle KE, Guerra CA, et al. : A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS neglected tropical diseases 2012;6(9):e1814 Pubmed Journal [PMC free article: PMC3435256] [PubMed: 22970336]
143.
Mendis K, Sina BJ, Marchesini P, Carter R : The neglected burden of Plasmodium vivax malaria. The American journal of tropical medicine and hygiene 64(1-2 Suppl):97–106 Pubmed [PubMed: 11425182]
144.
Singh B, Kim Sung L, Matusop A, Radhakrishnan A, Shamsul SSG, Cox-Singh J, et al. : A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet (London, England) 2004;363(9414):1017–24 Pubmed [PubMed: 15051281]
145.
Sutherland CJ, Tanomsing N, Nolder D, Oguike M, Jennison C, Pukrittayakamee S, et al. : Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. The Journal of infectious diseases 2010;201(10):1544–50 Pubmed Journal [PubMed: 20380562]
146.
Douglas NM, Lampah DA, Kenangalem E, Simpson JA, Poespoprodjo JR, Sugiarto P, et al. : Major burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance study. PLoS medicine 2013;10(12):e1001575; discussion e1001575 Pubmed Journal [PMC free article: PMC3866090] [PubMed: 24358031]
147.
Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, et al. : Vivax malaria: a major cause of morbidity in early infancy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(12):1704–12 Pubmed Journal [PMC free article: PMC4337979] [PubMed: 19438395]
148.
Genton B, D’Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, et al. : Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS medicine 2008;5(6):e127 Pubmed Journal [PMC free article: PMC2429951] [PubMed: 18563961]
149.
Kochar DK, Das A, Kochar SK, Saxena V, Sirohi P, Garg S, et al. : Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. The American journal of tropical medicine and hygiene 2009;80(2):194–8 Pubmed [PubMed: 19190212]
150.
Alexandre MA, Ferreira CO, Siqueira AM, Magalhães BL, Mourão MPG, Lacerda MV, et al. : Severe Plasmodium vivax malaria, Brazilian Amazon. Emerging infectious diseases 2010;16(10):1611–4 Pubmed Journal [PMC free article: PMC3294402] [PubMed: 20875292]
151.
Nosten F, McGready R, Simpson JA, Thwai KL, Balkan S, Cho T, et al. : Effects of Plasmodium vivax malaria in pregnancy. Lancet (London, England) 1999;354(9178):546–9 Pubmed [PubMed: 10470698]
152.
William T, Menon J, Rajahram G, Chan L, Ma G, Donaldson S, et al. : Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia. Emerging infectious diseases 2011;17(7):1248–55 Pubmed Journal [PMC free article: PMC3381373] [PubMed: 21762579]
153.
Barber BE, William T, Grigg MJ, Menon J, Auburn S, Marfurt J, et al. : A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013;56(3):383–97 Pubmed Journal [PubMed: 23087389]
154.
Grigg MJ, William T, Barber BE, Parameswaran U, Bird E, Piera K, et al. : Combining parasite lactate dehydrogenase-based and histidine-rich protein 2-based rapid tests to improve specificity for diagnosis of malaria Due to Plasmodium knowlesi and other Plasmodium species in Sabah, Malaysia. Journal of clinical microbiology 2014;52(6):2053–60 Pubmed Journal [PMC free article: PMC4042751] [PubMed: 24696029]
155.
Gogtay N, Kannan S, Thatte UM, Olliaro PL, Sinclair D : Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. The Cochrane database of systematic reviews 2013;(10):CD008492 Pubmed Journal [PMC free article: PMC6532731] [PubMed: 24163021]
156.
Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale (Policy brief). Geneva: World Health Organization 2016; Website
157.
Guide to G6PD deficiency rapid diagnostic testing to support P. vivax radical cure. World Health Organization, Geneva 2018; Website
158.
Galappaththy GNL, Tharyan P, Kirubakaran R : Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. The Cochrane database of systematic reviews 2013;(10):CD004389 Pubmed Journal [PMC free article: PMC6532739] [PubMed: 24163057]
159.
Radeva-Petrova D, Kayentao K, ter Kuile FO, Sinclair D, Garner P : Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment. The Cochrane database of systematic reviews 2014;(10):CD000169 Pubmed Journal [PMC free article: PMC4498495] [PubMed: 25300703]
160.
Management of severe malaria - A practical handbook, 3rd edition. Geneva: World Health Organization 2013; Website
161.
Sinclair D, Donegan S, Isba R, Lalloo DG : Artesunate versus quinine for treating severe malaria. The Cochrane database of systematic reviews 2012;(6):CD005967 Pubmed Journal [PMC free article: PMC6532684] [PubMed: 22696354]
162.
Information note on delayed haemolytic anaemia following treatment with artesunate. Geneva: World Health Organization 2013; Website
163.
Hendriksen ICE, Mtove G, Kent A, Gesase S, Reyburn H, Lemnge MM, et al. : Population pharmacokinetics of intramuscular artesunate in African children with severe malaria: implications for a practical dosing regimen. Clinical pharmacology and therapeutics 2013;93(5):443–50 Pubmed Journal [PMC free article: PMC3630454] [PubMed: 23511715]
164.
Zaloumis SG, Tarning J, Krishna S, Price RN, White NJ, Davis TME, et al. : Population pharmacokinetics of intravenous artesunate: a pooled analysis of individual data from patients with severe malaria. CPT: pharmacometrics & systems pharmacology 2014;3 e145 Pubmed Journal [PMC free article: PMC4259998] [PubMed: 25372510]
165.
Esu E, Effa EE, Opie ON, Uwaoma A, Meremikwu MM : Artemether for severe malaria. The Cochrane database of systematic reviews 2014;(9):CD010678 Pubmed Journal [PMC free article: PMC4455227] [PubMed: 25209020]
166.
Okebe J, Eisenhut M : Pre-referral rectal artesunate for severe malaria. The Cochrane database of systematic reviews 2014;(5):CD009964 Pubmed Journal [PMC free article: PMC4463986] [PubMed: 24869943]
167.
Rectal artesunate for pre-referral treatment of severe malaria. Geneva: World Health Organization 2017; Website
168.
Prequalification programme: A United Nations programme managed by WHO. Geneva: World Health Organization 2009; World Health Organization 2021; Website
169.
Tools for monitoring antimalarial drug efficacy. Geneva: World Health Organization 2019; Website
170.
Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization 2009; Website
171.
Methods and techniques for clinical trials on antimalarial drug efficacy: Genotyping to identify parasite populations. World Health Organization, Geneva 2008; Website
172.
Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010-2019). Geneva: World Health Organization 2020; Website
173.
Ajayi IO, Browne EN, Bateganya F, Yar D, Happi C, Falade CO, et al. : Effectiveness of artemisinin-based combination therapy used in the context of home management of malaria: a report from three study sites in sub-Saharan Africa. Malaria journal 2008;7 190 Pubmed Journal [PMC free article: PMC2567328] [PubMed: 18822170]
174.
A practical handbook on the pharmacovigilance of antimalarial medicines. Geneva: World Health Organization 2008; Website
175.
von Seidlein L, Greenwood BM : Mass administrations of antimalarial drugs. Trends in parasitology 2003;19(10):452–60 Pubmed [PubMed: 14519583]
176.
Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Björkman A : Malaria eradication on islands. Lancet (London, England) 2000;356(9241):1560–4 Pubmed [PubMed: 11075770]
177.
Kondrashin A, Baranova AM, Ashley EA, Recht J, White NJ, Sergiev VP : Mass primaquine treatment to eliminate vivax malaria: lessons from the past. Malaria journal 2014;13 51 Pubmed Journal [PMC free article: PMC3931915] [PubMed: 24502194]
178.
Communicable disease surveillance and response systems: guide to monitoring and evaluating. Geneva: World Health Organization 2006; Website
179.
WHO technical brief for countries preparing malaria funding requests for the Global Fun (2020-2022). Geneva: World Health Organization 2020; Website
180.
Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. : [GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction]. Gaceta sanitaria 32(2):166.e1–166.e10 Pubmed Journal [PubMed: 28822594]
181.
Moberg J, Oxman AD, Rosenbaum S, Schünemann HJ, Guyatt G, Flottorp S, et al. : The GRADE Evidence to Decision (EtD) framework for health system and public health decisions. Health research policy and systems 2018;16(1):45 Pubmed Journal [PMC free article: PMC5975536] [PubMed: 29843743]
182.
GRADE Handbook: Introduction to GRADE Handbook. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group 2013; Website
183.
World Health Organization (2021). Weekly Epidemiological Record, 2021, vol. 96, 50 [full issue]. Weekly Epidemiological Record 2021;96(50):13–15 Website
184.
Malaria Policy Advisory Group (MPAG) meeting (October 2021). Geneva: World Health Organization 2021; 15–16 Website
185.
Meeting of Strategic Advisory Group of Experts on Immunization, October 2021: conclusions and recommendations. Geneva: World Health Organization 2021; Website
186.
WHO malaria terminology, 2021 update. Geneva: World Health Organization 2021; Website
© World Health Organization 2022.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

Some rights reserved. This work is available under the Creative Commons AttributionNonCommercial-ShareAlike 3.0 IGO license (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this license, you may copy, redistribute and adapt the work for noncommercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the license shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Bookshelf ID: NBK579020

Views

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...